Drugs / Repository corticotropin injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01906658 | Jul 2013 → Nov 2014 | amyotrophic lateral sclerosis | Mallinckrodt | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Mallinckrodt | Results Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research gcs-web.com ↗
Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Mallinckrodt | Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research gcs-web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Repository corticotropin injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01906658 ↗ |
| Route | Subcutaneous | “Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks” NCT01906658 ↗ |